Necessary stem cell transplantation using myeloablative therapy for myelodysplastic syndrome with progression of genotypic abnormalities and TP53 dysfunction in a young adult.

Abstract

A 14-yr-old male was admitted to our hospital with MDS and the chromosomal abnormality 45,XY,der(5;17)(p10;q10). He rapidly developed karyotype abnormalities, accompanied by the loss of tumor suppressor gene TP53 function. He suffered an early relapse after reduced-intensity-conditioning SCT and ultimately required myeloablative therapy before a second SCT. We consider that the analysis of TP53 mutations is essential when planning the treatment of patients with MDS.

• Authors: Yuya Sato, Hidemitsu Kurosawa, Keitaro Fukushima, Mayuko Okuya, Hiromasa Yabe, Osamu Arisaka
• Journal: Pediatric transplantation (Pediatr Transplant) Vol. 18 Issue 7 Pg. E255-7 (Nov 2014) ISSN: 1399-3046 [Electronic] Denmark
• PMID: 25130056 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Chemical References

• Myeloablative Agonists
• TP53 protein, human
• Tumor Suppressor Protein p53

Topics

• Adolescent
• Chromosome Aberrations
• Disease Progression
• Gene Deletion
• Genotype
• Humans
• Karyotyping
• Male
• Mutation
• Myeloablative Agonists (therapeutic use)
• Myelodysplastic Syndromes (genetics, therapy)
• Prognosis
• Risk Factors
• Stem Cell Transplantation
• Tumor Suppressor Protein p53 (metabolism)